menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

Latest News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

May 23, 2024

【MoneyDJ】昱厚擬辦現增上限800萬股 加速推進新藥臨床試驗

Press

April 29, 2024

【鉅亨網】台灣生技業進入第三波浪潮 谷月涵看好4大類60家潛力公司出線

Press

April 27, 2024

【經濟日報B2】興櫃一周回顧／昱厚生技勁揚四成 居冠

Press

April 25, 2024

【工商時報B4】鼻噴新藥夯 昱厚：洽談授權中

Press

April 25, 2024

【鉅亨網】昱厚治療新冠新藥臨床二a數據優越 獲美國BARDA邀請會議

Press